D-0271-2021 Class II Terminated
FDA drug recall D-0271-2021 was initiated by Teva Pharmaceuticals USA on Feb 10, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable… The recall status is terminated (terminated May 15, 2024). Affected quantity: 50 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 3, 2021
- Initiation Date
- Feb 10, 2021
- Termination Date
- May 15, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 50 vials
Product description
Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), packaged in 10X20 ML Single Use Vials per tray (NDC 0703-5075-03); Rx only, TEVA Pharmaceuticals USA, INC., North Wales, PA 19454.
Reason for recall
Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.
Distribution pattern
Product was distributed nationwide in the USA and Puerto Rico.
Code information
Lot # 31326582B, exp. date 02/2022; Lot # 31326964B, exp. date 04/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0271-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026